HALO
NASDAQ · Biotechnology
Halozyme Therapeutics Inc
$103.63
-19.33 (-15.72%)
Financial Highlights (FY 2026)
Revenue
1.52B
Net Income
344.42M
Gross Margin
83.6%
Profit Margin
22.7%
Rev Growth
+28.4%
D/E Ratio
43.89
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 83.6% | 83.6% | 67.3% | 67.3% |
| Operating Margin | 33.2% | 29.9% | -6.4% | -7.2% |
| Profit Margin | 22.7% | 21.6% | -5.8% | -7.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.52B | 1.18B | 1.30B | 1.05B |
| Gross Profit | 1.27B | 988.71M | 873.05M | 707.65M |
| Operating Income | 503.81M | 353.19M | -82,975,143 | -75,519,990 |
| Net Income | 344.42M | 241.45M | -74,995,325 | -75,300,768 |
| Gross Margin | 83.6% | 83.6% | 67.3% | 67.3% |
| Operating Margin | 33.2% | 29.9% | -6.4% | -7.2% |
| Profit Margin | 22.7% | 21.6% | -5.8% | -7.2% |
| Rev Growth | +28.4% | +28.4% | +13.4% | +1.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 6.82B | 6.82B | 2.05B | 2.54B |
| Total Equity | 155.43M | 155.43M | 5.54B | 5.77B |
| D/E Ratio | 43.89 | 43.89 | 0.37 | 0.44 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 587.13M | 434.47M | -91,476,031 | -72,949,593 |
| Free Cash Flow | — | — | -86,399,966 | -67,262,012 |